Table 1.
Patient demographics
| Healthy controls | Mild/Moderate | Severe – survivors | Severe-fatal | |
|---|---|---|---|---|
| n = | 29 | 42 | 89 | 41 |
| Age (S.D.)a,b | 45.3 (10.1) | 58.0 (15.7) | 65.0 (11.2) | 69.1 (8.7) |
| Male/Femaleb | 16/13 | 16/26 | 72/17 | 32/9 |
| BMI (S.D.)b | 26.9 (5.7) | 24.4 (4.1) | 28.2 (5.6) | 27.6 (5.5) |
| Obese (BMI > 30)b | 20% | 14% | 35% | 34% |
| Nausea/Vomiting | / | / | 9% | 7% |
| Diarrhea | / | / | 6% | 5% |
| Medications at First Sampling Timepoint | ||||
| PPIb | 0% | 20% | 55% | 62% |
| Antibioticsb | 0% | 16% | 37% | 40% |
| Immunosuppressivesb | 0% | 20% | 61% | 65% |
| Preexisting Comorbidities | ||||
| Hypertension | 34% | 49% | 45% | |
| Dyslipidemiab | 9% | 24% | 30% | |
| Diabetes | 17% | 22% | 25% | |
| Respiratory – COPD/Asthma | 20% | 8% | 15% | |
| Chronic Kidney Disease | 3% | 4% | 8% | |
| Previous Neoplasia | 20% | 15% | 22% | |
ap < 0.05 Healthy Controls versus all COVID-19 patients.
bp < 0.05 Mild/Moderate versus Severe COVID-19.
PPI – Pantoprazole; Omeprazole.
Antibiotics – Amoxicillin; Azithromycin; Sulfamethoxazole; Clarithromycin.
Immunosuppressives – Dexamethasone; Methylprednisolone; Prednisolone.